Activation of the human complement system by pigmented and hypopigmented mycelia of the fungus Fonsecaea pedrosoi

Mycoses

Volumn 54, Issue 5, 2011, Pages

  Pinto, Lysianne ^a   Granja, Luiz Fernando Zmetek ^a   Alviano, Daniela Sales ^b   da Silva, Maria Helena ^a   Alviano, Celuta Sales ^b   Ejzemberg, Regina ^a  

^a Departamento de Imunologia do Instituto de Microbiologia   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Complement system; Fonsecaea pedrosoi; Melanised fungi; Pathogenesis

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C9; ZYMOSAN;

ARTICLE; CHROMOMYCOSIS; COMPLEMENT ACTIVATION; COMPLEMENT FIXATION TEST; COMPLEMENT SYSTEM; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FONSECAEA PEDROSOI; FUNGUS GROWTH; HUMAN; HYPOPIGMENTATION; IMMUNOFLUORESCENCE; MYCELIUM; NONHUMAN; OXYGENATION; PIGMENTATION; PRIORITY JOURNAL;

ADULT; ASCOMYCOTA; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; CULTURE MEDIA; DARKNESS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMAN EXPERIMENTATION; HUMANS; MICROSCOPY, FLUORESCENCE; MYCELIUM; MYCOLOGY; PIGMENTS, BIOLOGICAL;

FONSECAEA PEDROSOI; FUNGI;

EID: 80052805067     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2010.01956.x     Document Type: Article

References (31)

1. Dunkelberger JR, Song WC. Complement and its role in innate and adaptive immune responses. Cell Res 2010; 20: 34-50.
2. Volanakis JE, Frank MM. The Human Complement System in Health and Disease. New York: Marcel Dekker, 1998.
3. Kozel TR. Complement activation by pathogenic fungi. Res Immunol 1998; 149: 309-20.
4. Speth C, Rambach G, Würzner R, Lass-Flörl C. The role of complement in invasive fungal infections. Mycoses 2008; 51: 477-96.
5. Lopez Martinez R, Mendez Tovar LJ. Chromoblastomycosis. Clin Dermatol 2007; 25: 188-94.
6. d'Avila SC, Pagliari C, Duarte MI. The cell mediated immune reaction in the cutaneous lesion of chromoblastomycosis and their correlation with different clinical forms of the disease. Mycopathologia 2003; 156: 51-60.
7. Santos AL, Palmeira VF, Rozental S et al. Biology and pathogenesis of Fonsecaea pedrosoi, the major etiologic agent of chromoblastomycosis. FEMS Microbiol Rev 2007; 31: 570-91.
8. Cooper BH. Phialophora verrucosa and other chromoblastomycosis fungi. In: Szanizlo PJ (ed.), Fungal Dimorphism with Emphasis on Fungi Pathogenic for Humans. New York: Plenum Press, 1985: 263-80.
9. Alviano CS, Farbiarz SR, De Souza W, Angluster J, Travassos LR. Characterization of Fonsecaea pedrosoi melanin. J Gen Microbiol 1991; 137: 837-44.
10. Gómez BL, Nosanchuk JD. Melanin and fungi. Curr Opin Infect Dis 2003; 16: 91-96.
11. Rosas AL, Nosanchuk JD, Gomez BL, Edens WA, Henson JM, Casadevall A. Isolation and serological analyses of fungal melanins. J Immunol Methods 2000; 244: 69-80.
12. Romero-Martinez R, Wheeler M, Guerrero-Plata A, Rico G, Torres-Guerrero H. Biosynthesis and functions of melanin in Sporothrix schenckii. Infect Immun 2000; 68: 3696-703.
13. Wang Y, Casadevall A. Susceptibility of melanized and nonmelanized Cryptococcus neoformans to the melanin-binding compounds trifluoperazine and chloroquine. Antimicrob Agents Chemother 1996; 40: 541-5.
14. Borsos T, Rapp HJ. Hemolysin titration based on fixation of the activated first component of complement: evidence that one molecule of hemolysin suffices to sensitize an erythrocyte. J Immunol 1965; 95: 559-66.
15. Mayer MM. Complement and complement fixation. In: Kabat EA, Mayer MM (eds), Experimental Immunochemistry, 2nd edn. Springfield: Thomas Publisher, 1961: 133-240.
16. Voller A, Bidwell D. Enzyme-linked immunosorbent assay. In: Rose NR, Friedman H, Faley J (eds), Manual of Clinical Laboratory. Immunology, 3a edn. Washington, D.C: American Society for Microbiology, Cap.17, 1986: 99-109.
17. Bonifaz A, Carrasco-Gerard E, Saúl A. Chromoblastomycosis: clinical and mycologic experience of 51 cases. Mycoses 2001; 44: 1-7.
18. Selander B, Mårtensson U, Weintraub A et al. Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2. J Clin Invest 2006; 116: 1425-34.
19. Alviano DS, Franzen AJ, Travassos LR et al. Melanin from Fonsecaea pedrosoi induces production of human antifungal antibodies and enhances the antimicrobial efficacy of phagocytes. Infect Immun 2004; 72: 229-37.
20. Torinuki W, Okohchi K, Takematsu H, Tagami H. Activation of the alternative complement pathway by Fonsecaea pedrosoi. J Invest Dermatol 1984; 83: 308-10.
21. Mold C, Gewurz H, Du Clos TW. Regulation of complement activation by C-reactive protein. Immunopharmacology 1999; 42: 23-30.
22. Gupta G, Surolia A. Collectins: sentinels of innate immunity. Bioessays 2004; 29: 452-64.
23. Garlanda C, Bottazzi B, Salvatori G et al. Pentraxins in innate immunity and inflammation. Novartis Found Symp 2006; 279: 80-86.
24. Souza ET, Silva-Filho FC, De Souza W, Alviano CS, Angluster J, Travassos LR. Identification of sialic acids on the cell surface of hyphae and conidia of the human pathogen Fonsecaea pedrosoi. J Med Vet Mycol 1986; 24: 145-54.
25. Giannakis E, Male DA, Ormsby RJ et al. Multiple ligand binding sites on domain seven of human complement factor H. Int Immunopharmacol 2001; 1: 433-43.
26. Jacobson ES. Pathogenic roles for fungal melanins. Clin Microbiol Rev 2000; 13: 708-17.
27. Nosanchuk JD, Casadevall A. The contribution of melanin to microbial pathogenesis. Cell Microbiol 2003; 5: 203-23.
28. Mednick AJ, Nosanchuk JD, Casadevall A. Melanization of Cryptococcus neoformans affects lung inflammatory responses during cryptococcal infection. Infect Immun 2005; 73: 2012-9.
29. Rosas AL, MacGill RS, Nosanchuk JD, Kozel TR, Casadevall A. Activation of the alternative complement pathway by fungal melanins. Clin Diagn Lab Immunol 2002; 9: 144-8.
30. Petty HR, Francis JW, Todd RF, Petreguim P, Boxer LA. Neutrophil C3bi receptors: formation of membrane clusters during cell triggering requires intracellular granules. J Cell Physiol 1987; 133: 235-42.
31. Wang Y, Aisen P, Casadevall A. Cryptococcus neoformans melanin and virulence: mechanism of action. Infect Immun 1995; 63: 3131-6.